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Abstract
Background: HIV-HCV co-infection is associated with accelerated progression to hepatic fibrosis, cirrhosis and
hepatocellular carcinoma than HCV mono-infection. The contribution of innate immunity during HIV-HCV co-
infection has been a relatively under-investigated area. Natural killer (NK) cells are pivotal sentinels of innate
immunity against viruses and tumour cells. In this study we evaluated the effect of HIV-HCV co-infection on
peripheral blood NK cell subsets with emphasis on the phenotype of CD56bright NK cells.
Methods: Sixty patients were included in the study; HIV mono-infected (n = 12), HCV mono-infected (n = 15), HCV-HIV
co-infected (n = 21) and healthy controls (n = 16). PBMCs were isolated and immunophenotyping of NK cells was
performed by flowcytometry.
Results: We observed an expansion of CD56bright NK cell subset in HIV-HCV co-infection as compared to healthy
controls and HIV mono-infected group. All the infected groups had an upregulated expression of the activating
receptor NKG2D on CD56bright NK cells in comparison to healthy controls while not differing amongst themselves.
The expression of NKp46 in HIV-HCV co-infected group was significantly upregulated as compared to both HIV as well
as HCV mono-infections while NKp30 expression in the HIV-HCV co-infected group significantly differed as compared
to HIV mono-infection. The CD56bright NK cell subset was activated in HIV-HCV co-infection as assessed by the
expression of CD69 as compared to healthy controls but was significantly downregulated in comparison to HIV mono-
infection. CD95 expression on CD56bright NK cells followed the same pattern where there was an increased expression of
CD95 in HIV mono-infection and HIV-HCV co-infection as compared to healthy controls. In contrast to CD69 expression,
CD95 expression in HCV mono-infection was decreased when compared to HIV mono-infection and HIV-HCV co-
infection. Finally, expression of CXCR3 on CD56bright NK cells was increased in HIV-HCV co-infection in comparison to HIV
mono-infection while remaining similar to HCV mono-infection.
Conclusion: Thus, HIV-HCV co-infection is able to modulate the phenotype of CD56bright NK cell subset in a unique way
such that NKp46 and CXCR3 expressions are distinct for co-infection while both mono-infections have an additive effect
on CD56bright, CD69 with CD95 expressions. HCV mono-infection has a dominant effect on NKp30 expression while
NKG2D and CD127 expressions remained same in all the groups.
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Background
NK cells are effector cells of the innate immune system,
capable of destroying virus-infected and tumour cells with-
out prior sensitization [1, 2]. The majority of human NK
cells in peripheral blood are CD56dimCD16+ cells whereas
CD56brightCD16+/− cells only constitute approximately 10%
of the peripheral blood NK cell pool [3]. In addition,
CD56bright NK cells have high surface density expression
of type II membrane glycoprotein CD94, L-Selectin 62L,
CD127 and lymph node homing receptor CCR7 but low
expression of the low affinity IgG-Fc receptor III (CD16),
killer cell immunoglobulin-like receptors (KIRs) and cyto-
toxic molecules such as perforin and granzyme B [4].
Thus, NK cell subsets seem to perform distinct roles in
the immune response. CD56bright NK cells have more
regulatory functions by means of cytokine production
while CD56dim NK cells are primarily cytolytic in function
but produce significant amounts of cytokines when their
activating receptors are engaged [5]. This distinction is
however not absolute [6].
The chemokine receptor repertoire also differ among the
NK cell subsets with the expression of CXCR3 at a much
stronger density on CD56bright subset than CD56dim cells,
while the latter express CXCR1 and CX3CR1 exclusively
[5, 7]. The differential repertoires of chemokine receptors
and adhesion molecules endow NK cell subsets with di-
vergent migratory properties: the CD56bright subset
preferentially homes to secondary lymphoid organs
whereas the CD56dim cells home to acute inflammatory
sites [5, 7].
Persistent infections by HCV and HIV present unique
challenges to the immune system as they result in highly
chronic viral persistence which lasts indefinitely without
antiviral treatment [8]. In HIV infection, several studies
have shown functional impairment in NK cell cytokine
secretion and cytotoxicity. Both acute and chronic
untreated HIV infection is associated with alterations
in NK cell subset distribution, with partial loss of
CD56+CD16+ cells and expansion of CD56−CD16+ NK
cells having impaired cytolytic function, increased ac-
tivation markers and decreased cytokine production
[9, 10]. Similarly, HCV viral persistence has also been
shown to be associated with defective NK cell responses
in vivo both in the periphery and in the liver [7, 11]. NK
cell function was rescued after successful IFN-α therapy in
chronically HCV infected patients [12].
HIV infection is not only associated with changes in
NK cell subpopulation but also with marked alterations
in NK cell surface receptor expression and loss of func-
tion [13]. In HIV viremic patients, there is an overall de-
crease in surface receptor density of NKp46 and NKp30
found on freshly isolated NK cells and dysfunction in
NKp44 de novo expression upon stimulation in vitro
resulting in an NCR dull phenotype [14]. The proportion
of NKp46 and NKp30 expressing CD56dim NK cells and
their cytolytic activity was shown to decrease with dis-
ease progression [15].
Contrary to HIV infection, there is no consensus on
NCR expression during HCV infection. There are reports
that show increased proportions and density of NCRs in-
cluding NKG2C, NKp44, NKp30 and NKp46 [16, 17] while
the earlier reports of decreased expression of NKp46 have
not been subsequently confirmed [7]. In addition, couple
of recent studies have suggested that HCV infected cells
may selectively down regulate NKp30 and impair NK cell
function by this mechanism [14, 18, 19].
Nearly all NK cells express NKG2D which is considered
a potent activating receptor [20] that has the ability to trig-
ger cytotoxicity and at the same time capable of overriding
signals provided by other inhibitory receptors. Similar to
other NCRs, there is conflicting evidence with respect to
NKG2D expression which has been reported from being
up-regulated or down-regulated to being unchanged during
chronic HCV infection [16, 21].
A number of studies have revealed CD56bright and
CD56dim NK cells as separate NK cell subsets rather than a
homogenous population having unique roles in the innate
immune response [7]. By virtue of their ability to produce
different cytokines, CD56bright NK cells might play an im-
portant role in early immune responses as well as in shap-
ing of the adaptive response [5]. Not much is known about
the impact of HIV and HCV co-infection on CD56bright NK
cells. In the current study, we therefore investigated the
phenotype of CD56bright NK cells in HIV-HCV co-infected
subjects and compared these with HCV and HIV mono-
infected patients as well as with healthy controls. We
found that HIV-HCV co-infection is able to modulate the
phenotype of CD56bright NK cells in a complex way.
Results
Frequency of CD56bright NK cells
We defined NK cells as CD3−CD14−CD19− lymphocytes ex-
pressing either CD16 or CD56 or both as described previ-
ously [10]. Utilizing CD56 and CD16 we defined CD56bright
NK cell population in peripheral blood as shown in Fig. 1a.
The percentage of CD56brightCD16+/− NK cells in HIV and
HCV mono-infections did not differ significantly as
compared to the healthy controls. On the other hand HIV-
HCV co-infection had significant upregulation of
CD56brightCD16+/− NK cells as compared to healthy controls.
As compared to mono-infections HIV-HCV co-infection
had an upregulated expression of CD56brightCD16+/− NK
cells than HIV mono-infection only. Although HCV
mono-infection showed a trend towards increased
CD56brightCD16+/− NK cells, only HIV-HCV co-infection
resulted in an increase that was significantly different from
both healthy controls and HIV mono-infection (Fig. 1b).
The log percentage of CD56bright NK cells expressing
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Fig. 1 Increased CD56brightCD16+/- NK cells in HIV-HCV co-infection. a Representative gating scheme for identification of CD56brightCD16+/- NK cells.
b Comparison of percentage of the CD56bright NK cell subpopulation in control subjects (n = 13), HIV seropositive (n = 12), HIV-HCV co-infected (n = 21)
and HCV mono-infected individuals (n = 15) on CD56bright CD16+/− NK cells. (c) Comparison of log percentage of the CD56bright NK cells expressing
CD16 in control subjects (n = 13), HIV seropositive (n = 12), HIV-HCV co-infected (n = 21) and HCV mono-infected individuals (n = 15) on CD56+CD16+/-
NK cells. *, P < 0.05; ns - not significant (P > 0.05). In the dot plot figure horizontal line represents % Mean ± SEM and Log % Mean ± SEM respectively
Bhardwaj et al. Virology Journal  (2016) 13:67 Page 3 of 12
CD16 in HIV-HCV co-infected patients also differed sig-
nificantly as compared to healthy controls and HIV
mono-infected group (Fig. 1c).
Our data indicate that HIV-HCV co-infection is associ-
ated with an increase of CD56bright NK cells. In addition
CD16+CD56bright NK cells in all the infected groups had a
significant positive correlation with CD56brightCD16+/− NK
cells (Table 1).
Expression of NKG2D and NCRs
The representative flow cytometry plots of NKG2D and
NCRs, NKp46 and NKp30 expression on CD56bright NK
cells is shown in Fig. 2a. All the infected groups did not
differ significantly for NKG2D expression on the CD56bright
NK cell subset; however its expression was significantly up-
regulated on all the infected groups as compared to healthy
controls (Fig. 2b).
The expression of NKp46 on CD56bright NK cells was
significantly down-regulated in HIV mono-infected group
as compared to healthy controls (Fig. 2c). In contrast, it
was up-regulated on HIV-HCV co-infected group as
compared to HIV and HCV mono-infected groups. How-
ever, the frequency of NKp46+CD56bright NK cells did not
differ significantly between HIV and HCV mono-
infections (Fig. 2c).
The log percentage of NKp30+CD56bright NK cells in
all the infected groups did not differ significantly as
compared to healthy controls. NKp30 expression on
CD56bright NK cells was significantly downregulated in
HIV mono-infected group than both HIV-HCV co-
infection and HCV mono-infection (Fig. 2d) while in
case of HCV mono-infected group NKp30 expression
differed significantly as compared to HIV mono-infected
group only (Fig. 2d). Also in HIV mono-infected group
the expression of NKp46 on CD56bright NK cells had a
direct correlation with the expression of NKp30 on CD5
6bright NK cells (Table 1), while in HCV mono-infected
patients NKp46+CD56bright NK cells were positively cor-
related with the expression of CXCR3 on CD56bright NK
cells (Table 1).
Activation status, expression of Fas receptor (CD95) and
proliferative capacity of CD56bright NK cells
Figure 3a shows the representative flow cytometry plots of
CD69, CD95 and CD127 expressions on CD56bright NK
cells. The log percentage expression of CD69 which is an
early activation marker [22], was found to be considerably
increased among CD56bright NK cells in HIV mono-infected
and HIV-HCV co-infected groups in comparison to healthy
controls suggesting a heightened status of immune activa-
tion in HIV mono-infected and HIV-HCV co-infected
patients (Fig. 3b). Among the infected groups HIV-HCV co-
infected and HCV mono-infected groups showed lower
CD69 expression than HIV mono-infected group (Fig. 3b).
The finding of a more ‘HCV-like’ phenotype in HIV-HCV
co-infection suggests that reduced CD69 expression might
also be caused by an increase of CD56bright NK cells that
lack CD69 in the HIV-HCV co-infected cohort.
During chronic viral infections, activated immune cells
(lymphocytes) or the highly exhausted cells are deleted
by apoptosis [23]. CD95 (Fas receptor) binds to CD95L
(Fas ligand) and induces apoptosis. The expression of
CD95 on CD56bright NK cells was upregulated in both
HIV mono-infected and HIV-HCV co-infected groups as
compared to healthy controls (Fig. 3c). At the same
time, CD95 expression was downregulated on the
CD56bright NK cell subset in HCV mono-infection in
comparison to both HIV mono-infection and HIV-
HCV co-infection (Fig. 3c).
The expression of CD127 on CD56bright NK cells is
associated with high proliferative capacity. Expression of
Table 1 Correlation between various NK cell receptors
HIV mono-infection CD56brightCD16+/− NK cells NKp30+CD56bright NK cells
CD16+CD56bright NK cells Correlation coefficient rs = 0.742** NA
Sig. (2 tailed) P < 0.01 NA
NKp46+CD56bright NK cells Correlation coefficient NA rs = 0.633*
Sig. (2 tailed) NA P < 0.05
HIV-HCV co-infection CD56brightCD16+/− NK cells CD127+CD56bright NK cells
CD16+CD56bright NK cells Correlation coefficient rs = 0.810** NA
Sig. (2 tailed) P < 0.01 NA
CD69+CD56bright NK cells Correlation coefficient NA rs = −0.433*
Sig. (2 tailed) NA P < 0.05
HCV mono-infection CXCR3+CD56bright NK cells
NKp46+CD56bright NK cells Correlation coefficient rs = 0.587* NA
Sig. (2 tailed) P < 0.05 NA
rs Spearman coefficient; NA not applicable; *, P < 0.05; **, P < 0.01
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Fig. 2 Upregulated expression of NKG2D and NCRs on CD56brightCD16+/- NK cells in HIV-HCV co-infection. a Representative examples of flow cytometric
analysis of C-type lectin receptor NKG2D and NCRs NKp46 and NKp30 expression on CD56brightCD16+/- NK cells. b Surface expression of NKG2D on
CD56brightCD16+/- NK cell subset in healthy controls (n= 15), HIV mono-infected (n =12), HIV-HCV co-infected (n= 12) and HCV mono-infected patients
(n= 15). c Surface expression of NKp46 on CD56brightCD16+/- NK cell subset in healthy controls (n= 13), HIV mono-infected (n =11), HIV-HCV co-infected
(n= 13) and HCV mono-infected patients (n= 15). d Surface expression of NKp30 on CD56brightCD16+/- NK cell subset in healthy controls (n= 16), HIV mono-
infected (n =11), HIV-HCV co-infected (n= 12) and HCV mono-infected patients (n= 12). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns - not significant (P > 0.05).
In the dot plot figures horizontal line represents Log % Mean ± SEM
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Fig. 3 Expression of CD69, CD95 and CD127. a Representative dot plots obtained from the measurement of CD69, CD95 and CD127 expression on
CD56brightCD16+/- NK cells by flow cytometry. b CD69 expression on CD56brightCD16+/- NK cells in healthy controls (n = 10), HIV mono-infected (n =12),
HIV-HCV co-infected (n = 21) and HCV mono-infected patients (n = 12). c CD95 expression on CD56brightCD16+/- NK cells in healthy controls (n = 13),
HIV mono-infected (n =12), HIV-HCV co-infected (n= 14) and HCV mono-infected patients (n= 15). d CD127 expression on CD56brightCD16+/- NK cells in
healthy controls (n= 10), HIV mono-infected (n =12), HIV-HCV co-infected (n= 21) and HCV mono-infected patients (n= 12). *, P < 0.05; **, P < 0.01; ***,
P < 0.001; ns - not significant (P > 0.05). In the dot plot figures horizontal line represents % Mean± SEM
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CD127 was downregulated in all the infected groups as
compared to healthy controls, although this decrease was
not significant (Fig. 3d). Between the infected groups there
was no difference for CD127 expression on CD56bright NK
cells (Fig. 3d).
In addition, the expression of CD69 on CD56brightNK
cells had a negative correlation with CD127+CD56bright
NK cells (Table 1).
Chemokine receptor CXCR3 expression
Among the NK cell subsets CXCR3 is expressed more on
CD56bright than CD56dim subset. As compared to healthy
controls, the expression of CXCR3 on CD56bright NK cells
was significantly down-regulated in HIV mono-infected
group (Fig. 4b). Interestingly, CXCR3 expression was higher
on CD56bright NK cells in the HIV-HCV co-infected group
as compared to the HIV mono-infected group (Fig. 4b).
Finally we did not find any correlation between the
HCV or HIV viral load with the fractions of different
CD56bright NK subsets that were assessed.
Discussion
HIV-HCV co-infected individuals progress more rapidly
to fibrosis, cirrhosis, liver failure and hepatocellular car-
cinoma than patients infected with HCV alone [7, 24].
Both HIV and HCV mono-infections have been shown
to have impaired NK cell functions and skewed subset
distributions [7, 9]. However, the impact of HIV-HCV
co-infection on phenotypic alterations of NK cell subsets
is not well understood. Here, we investigated the pheno-
type of CD56bright NK cells in HIV-HCV co-infected
individuals and compared it with HIV or HCV mono
infected patients as well as with healthy controls. In our
study we found an expansion of CD56bright NK cell sub-
set in HIV-HCV co-infected cohort similar to reported
for HCV mono-infection [25, 26] although there is a
study reporting no change in CD56bright NK cell compart-
ment in HCV mono-infection [27]. In line with our find-
ings, in a cohort of female patients chronically infected
with HCV, the proportion of CD56bright NK cells was
increased as compared to HCV resolvers and healthy con-
trols [25]. The same increased percentage of CD56bright
NK cells was found among individuals with a positive tu-
berculin skin test compared with patients with overt tu-
berculosis and normal controls [28]. The significance of
increased CD56bright cells in our study is currently un-
clear. Expansion of CD56bright NK cells in HCV infection
might have resulted from a decreased rate of differenti-
ation towards CD56dim NK cells in these studies. However,
in our study the percentage of total NK cells and CD56dim
NK cells did not differ among all the groups (data not
shown). The increased percentage of CD16 expression on
CD56bright NK cells in HIV-HCV co-infected patients
indicated a phenotypic shift towards CD56dim NK cells and
their subsequent role in antibody dependent cellular
cytotoxicity (ADCC). Increased expression of CD16 on
CD56bright NK cells is also reported in HIV-1 infected
individuals which is partially restored after ART [29].
NK cell function is primarily regulated by balance
between activating and inhibitory receptors. NKG2D
and NCRs are one of the main NK cell activating recep-
tors that are required for NK cell effector functions.
NKG2D and NCRs are differentially expressed by differ-
ent subsets of NK cells [20, 30]. We analysed the expres-
sion of NKG2D and NCRs (NKp30 and NKp46) on
CD56bright NK cell subset. NKG2D was upregulated in
all the three infected populations as compared to healthy
controls. The cytotoxic potential of all NK cell subsets
increases when stimulated with cytokines like IL-2 or IL-
12 in vitro [7]. This might be one of the reasons for the in-
creased expression of NCRs and NKG2D on CD56bright
NK cells in vivo as well in chronic viral infections.
In HIV viremic patients, there is an overall decrease of
NKp46 and NKp30 on NK cells [14] while in HCV infec-
tion couple of studies have shown reduced NKp30+ NK
cells. In our study, we did not observe a decreased NKp30
expression on CD56bright NK cells in HCV mono-infection.
Thus, reduced NKp46 and NKp30 on CD56bright NK cells
is a unique hallmark of HIV infection [14, 18, 19]. However
these results are not directly comparable or necessarily in
conflict as our results are focussed on the different frac-
tions of CD56bright NK cell subset.
In our study NKp46 expression on HIV-HCV co-
infected group differed significantly from both HIV and
HCV mono-infected groups while NKp30 expression
was increased on CD56bright NK cell subset in HIV-HCV
co-infected cohort which differed significantly as com-
pared to HIV mono-infected group. The finding of
increased frequency of NKp30 and NKp46 expressing
CD56bright NK cells in HIV-HCV co-infection as com-
pared to HIV mono-infection also supports a shift of the
populations either due to increased apoptosis of acti-
vated CD56bright NK cells or an increase of ‘HCV-like’
CD56bright NK cells in case of NKp30 expression while
indicating a unique and an important role of NKp46 in
HIV-HCV co-infection.
Immune activation is a hallmark of chronic viral infec-
tions like HIV [31]. HIV infected patients showed an
increased activation of CD56bright NK cells as compared to
HIV-HCV co-infected and HCV mono-infected groups as
measured by the expression of CD69. This might be
because of the ongoing residual viral replication even after
one year of ART [32]. The reduced expression of CD69 in
HIV-HCV co-infected cohort suggests a decreased activa-
tion status of CD56bright NK cells in HIV-HCV co-infection
than HIV mono-infection. However, it is unlikely that HCV
co-infection might ‘protect’ CD56bright NK cells from in-
creased immune activation. Alternatively, a loss of CD69
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Fig. 4 Increased chemokine receptor CXCR3 expression on CD56brightCD16+/− NK cells in HIV-HCV co-infection. a Representative dot plots obtained
from the measurement of CXCR3 expression on CD56brightCD16+/− NK cells by flow cytometry. b CXCR3 expression on CD56brightCD16+/− NK cells in
healthy controls (n = 10), HIV mono-infected (n =12), HIV-HCV co-infected (n = 21) and HCV mono-infected patients (n = 12). **, P < 0.01; ***, P < 0.001;
ns - not significant (P > 0.05). In the dot plot figure horizontal line represents Log % Mean ± SEM
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expressing CD56bright NK cells could be either due to in-
creased apoptosis or a relative increase of CD69 negative
NK cells in the HIV-HCV co-infected cohort or both. We
therefore analysed the expression of the apoptosis marker
CD95.
Immune cells undergo apoptosis as a result of chronic
activation or exhaustion during chronic viral infections.
Fas mediated apoptosis (FMA) is one of the mechanisms
by which cells undergo apoptosis [33]. The expression of
Fas receptor CD95 on CD56bright NK subset was higher in
HIV mono-infected patients. The same group also had the
high expression of CD69 on the CD56bright NK cells show-
ing a chronic systemic immune activation status. The in-
creased expression of CD69 as well as CD95 on CD56bright
NK cell subset in HIV treated patients may render activated
NK cells more prone to undergo apoptosis. Enhanced
susceptibility of NK cells to cell death by CD95-CD95L in
HIV infected viremic individuals has already been re-
ported by Kottilil et al. [34]. A number of reports show
increased expression of CD95 on various lymphocyte
subsets as a result of immune activation induced by
HIV viremia thereby facilitating lymphocyte apoptosis
[35, 36]. The expression of CD69 on CD56bright NK
cells in HIV-HCV co-infected group was closer to HCV
mono-infected group whereas the CD95 expression
behaved more similar to HIV treated mono-infected
group thus showing imprints of either infection.
CD127 (IL-7Rα receptor) is important for homeostatic
proliferation, particularly in lymphopenic settings when
remaining cells initiate a homeostatic response to repopu-
late the depleted compartment. The level of IL-7 and
expression patterns of CD127 are believed to be skewed in
HIV [37, 38]. Our study also demonstrated a skewed
expression of CD127 on CD56bright NK cells in all the
infected groups as compared to healthy controls, but the
difference was not significant. Chronic viral infections may
be associated with reduced CD127 in general.
Chemokine receptor CXCR3 and its ligands (particularly
IP-10) are associated with a type 1 response and recruit
lymphocytes to the liver [39, 40]. Kimball et al. [41] have
previously demonstrated an increased CXCR3 expression
on CD8+T cells from HIV-HCV co-infected patients as
compared to healthy controls. A recent study showed
HCV infection to be associated with significantly in-
creased frequency of CXCR3+ CD56bright NK cells but
these cells showed an impaired degranulation and IFN-γ
secretion in response to hepatic stellate cells (HSCs) [42].
In our study, we observed a decreased expression of the
frequency of CXCR3+ CD56bright NK cells in HCV mono-
infection as well as in HIV mono-infection, which was
even more pronounced than in HCV mono-infection. In
addition, our study showed an elevated expression of
CXCR3 on CD56bright NK cells in HIV-HCV co-infection
as compared to HIV and HCV mono-infected groups
which may reflect an effort to recruit more CD56bright NK
cells to liver in the wake of a co-infection.
One of the limitations of the current study is the lack of
NK cell functional data in terms of NK cell cytotoxicity and
cytokine secretion. Functional assays will reflect more
clearly on the real impact of HIV or HCV mono-infection
on HIV-HCV co-infection and may also help in deciphering
the complex phenotype observed in HIV-HCV co-infection
in our study.
In summary, the increased CD56bright NK cells in HIV-
HCV co-infection might be a compensatory mechanism to
recruit more immunoregulatory CD56bright NK cells. Even
though NKp30 and NKp40 expression was increased in
HIV-HCV co-infection, NKp40 expression was unique for
HIV-HCV co-infection as it behaved neither like HIV nor
HCV mono-infection. This observation may imply that
among NCRs, NKp46 seems to play an important role in
the cytotoxic potential of CD56bright NK cells and in com-
bating both HIV and HCV mono-infections. NKp30 ex-
pression was same for HCV mono-infection and HIV-HCV
co-infection indicating that chronic viral hepatic infections
do not have a dominant bearing on the expression of
NKp30 on CD56bright NK cells. While HIV and HCV
mono-infections differed for NKp30 expression, they
remained same for NKp46 expression on CD56bright NK
cells. Increased NKG2D expression in HIV and HCV
mono-infections and HIV-HCV co-infection rather reflects
a general feature of viral infections. Interestingly, CXCR3
expression increased in HIV-HCV co-infection vis-à-vis in
HIV and HCV mono-infections - probably caused by an
additional infection. It can also be speculated that increased
CD69 and CD95 expression on CD56bright NK cells in HIV
mono-infection are a reflection of their exhaustive pheno-
type. A summary of various NK cell receptors expression is
provided in Table 2.
Conclusion
HIV-HCV co-infection exhibits a complex imprinting of
the CD56bright NK cell phenotype. HIV-HCV co-infection
is characterized by an increased CD56bright NK cell popu-
lation. NKG2D expression behaves similarily in all the
infected groups. NKp46 expression is higher in HIV-HCV
co-infection than in both mono-infections and is thus
distinct for HIV-HCV co-infection, while NKp30 expres-
sion behaves more like in HCV mono-infection. The
expression of the activation marker CD69 and FasR CD95
is in between HIV and HCV mono-infections (closer to
HCV mono-infection and closer to HIV mono-infection
respectively) but clearly influenced by both HIV and HCV
mono-infections for CD69 and CD95 expressions. CD127
expression is same in all the groups. Expression of
CXCR3 in co-infection is clearly different as it is not
reduced as much as in either mono-infections so this
combination is also unique for HIV-HCV co-infection.
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Thus we see a complex phenotype of CD56bright NK cells
in HIV-HCV co-infection. Future functional studies may
investigate as to what extend these altered phenotypes
may influence the course of co-infection and which
factors are responsible for each individual to define how
HIV-HCV co-infection affects the CD56bright NK cells.
Methods
Study subjects
We obtained peripheral blood samples from 12 HIV sero-
positive subjects both treated [11] and untreated [1], 15
HCV mono-infected untreated subjects with replicative
HCV infection, 21 HIV-HCV co-infected subjects both
treated [17] and untreated [4] for HIV in the HIV out-
patient clinic of the Medizinische Hochschule Hannover
(MHH) but treatment naïve for HCV and 16 healthy con-
trols. All HCV infected subjects were also treatment naive
for hepatitis C during the study period. All study subjects
were recruited at the HIV and HCV outpatient clinic of
the Medizinische Hochschule Hannover (MHH) and of
the University Medical Centre, Hamburg-Eppendorf. All
study participants gave written, informed consent prior
to their participation. The study was approved by the
local ethics committee (Votum der Ethikkommission
der MHH No. 3150).
A summary of the demographical data of the studied
groups is shown in Table 3. Plasma HIV-1 RNA level was
measured with the COBAS TaqMan HIV-1 test (Roche
Diagnostics, Basel, Switzerland) with a lower limit of detec-
tion of 34 copies/ml.
Table 2 Summary of various NK cell receptors expression data
NK cell receptor HIV vs HC HIV-HCV vs HC HCV vs HC HIV-HCV vs HIV HIV-HCV vs HCV HIV vs HCV
CD56bright NK cells − ↑ − ↑ − −
CD16+CD56bright NK cells − ↑↑↑ − ↑↑↑ ↑↑ −
NKG2D+CD56bright NK cells ↑↑ ↑↑↑ ↑↑↑ − − −
NKp46+CD56bright NK cells ↓ − − ↑↑↑ ↑ −
NKp30+CD56bright NK cells − − − ↑↑ − ↓↓
CD69+CD56bright NK cells ↑↑↑ ↑↑ − ↓↓↓ − ↑↑↑
CD95+CD56bright NK cells ↑↑↑ ↑↑↑ − − ↑ ↑
CD127+CD56bright NK cells − − − − − −
CXCR3+CD56bright NK cells ↑↑↑ − − ↑↑ − −
Direction of the arrows documents upregulation or downregulation of NK receptor expression in respective comparisons. ↑ or ↓ = P < 0.05; ↑↑ or ↓↓ = P < 0.01; ↑↑↑
or ↓↓↓ = P < 0.001
Table 3 Summary and comparison of log values of demographic characteristics of study groups
Parameters HC HIV HIV-HCV HCV P value
(n=16) (n=12) (n=21) (n=15)
Mean age (years)±SD 43.8±3.3 45±5.5 47±7.6 48.5±5.8 0.15
Male/Female 7/5 8/4 16/5 7/8 0.34
HIV RNA, mean copies/ml Seronegative 6.1±3.5 5.7±3.0 N/A 0.76
Mean CD4+ T cell count (n/µl)±SD NT 6.1±0.5 5.8±0.7 NT 0.24
Treated/Untreated for HIV N/A 11/1 17/4 N/A 0.41
HCV RNA, mean copies/ml Seronegative N/A 13.0±2.9 14.5±1.1 0.12
n=4 (NA)
AST (U/L), mean 4.2±0.5 3.9±0.5 0.1
NT N/A n=2 (NA) n=1 (NA)
ALT (U/L), mean 4.2±0.7 4.0±0.7 0.36
NT N/A n=2 (NA) n=1 (NA)
γGT (U/L), mean 4.4±0.8 4.0±0.8 0.15
NT N/A n=2 (NA) n=1 (NA)
Billirubin (µmol/L), mean 2.3±0.6 2.4±0.4 0.72
NT N/A n=2 (NA) n=1 (NA)
Abbreviations: N/A not applicable, NT not tested, NA not available
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Absolute counts of CD4+ T cells, NK cells and other
lymphocyte subpopulations were determined by flow
cytometry using a cocktail of antibodies from Beckman
Coulter, California, USA either directed against CD45,
CD3, CD4 and CD8 or CD45, CD56, CD19, CD3 and
CD16.
Isolation of mononuclear cells
PBMCs were isolated from fresh blood as described
previously [17]. Aliquots of 107 PBMCs each were cryo-
preserved in heat-inactivated FCS supplemented with 10
% dimethyl sulfoxide (DMSO) (Merck, NJ, USA).
Phenotypic analysis of NK cells by flowcytometry
Staining and flow cytometric analysis was performed as de-
scribed before [10]. The Following monoclonal antibodies
were used in this study: Via probe PerCP, anti-CD19 PerCP,
anti-CD14 PerCP and anti-CD3 PerCP (BD Biosciences, CA,
USA) to exclude dead cells, B cells, monocytes and T cells,
respectively, and anti-CD56 PC7 (Beckman Coulter, CA,
USA) and anti-CD16 APC-H7 (BD Biosciences, CA, USA)
to identify NK cells. Additional antibodies that were used in-
clude: anti-CXCR3 APC (BD Biosciences, CA, USA), anti-
CD69 PE (Invitrogen, CA, USA), anti-CD127 PacBlue (BD
Biosciences, CA, USA), anti-CD95 APC (Biolegend, CA,
USA), anti-NKp30 APC (Beckman Coulter, CA, USA), anti-
NKp46 PE (Beckman Coulter, CA, USA), anti-NKG2D APC
(BD Biosciences, CA, USA). At least 1 million events
were acquired for each sample, using the BD Canto II (BD
Biosciences, CA, USA). Data were analysed with FlowJo 8.8.4
(TreeStar, Or, USA). Lymphocytes were defined by forward
and side scatter. CD3+, CD14+, CD19+, dead cells and cell
aggregates were removed from analysis based on PerCP and
Viaprobe cell viability staining and pulse width analysis.
Fluorescence minus one (FMO) staining was used to deter-
mine threshold values for the expression of each surface
marker.
Statistical analysis
GraphPad Prism (version 5.0) software was used for statis-
tical evaluation of the data. One-way ANOVA followed by
post hoc comparison by Bonferroni method was performed.
Kruskal-Wallis test was applied for CD16+CD56bright NK
cells followed by multiple comparisons by Mann-Whitney
after adjusting the probability level. The correlation
between various parameters was studied using Pearson/
Spearman correlation. The categorical data was analysed by
chi-square/Fisher’s exact test wherever necessary. The log
transformation was also applied for making the skewed data
normalized. P values less than 0.05 were considered
significant.
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